ASH
ASH: Carfilzomib increases survival in relapsed multiple myeloma
December 12, 2014Improved progression-free survival in relapsed multiple myeloma has been seen with the addition of carfilzomib to lenalidomide and dexamethasone therapy.
CAR cell engineering offers hope for patients with hard-to-treat blood disorders
December 27, 2013The use of chimeric antigen receptor (CAR) cell engineering was described in several studies presented at the 2013 ASH Annual Meeting in New Orleans.
Advances in cell engineering improve prognosis of haploidentical stem cell transplantation
December 27, 2013Genetically engineered cell therapies may bring hope to patients for whom standard treatments have been unsuccessful, according to two separate studies presented at the 2013 ASH Annual Meeting, in New Orleans, Louisiana.
Genetic driver of Waldenström macroglobulinemia identified
December 26, 2013In nearly one-third of patients with Waldenström macroglobulinemia, the disease is switched on by a specific genetic mutation. A new drug that blocks the defective gene can arrest the disease in animal models, according to research reported at the 2013 ASH Annual Meeting, in New Orleans.
Age alone should not limit access to stem cell transplants for patients with MDS
December 26, 2013Patients with myelodysplastic syndrome age 66 to 74 years did as well with stem cell transplantation as patients age 60 to 65 years. This research was presented at the 2013 ASH Annual Meeting, in New Orleans.
Drug induces morphologic, molecular, and clinical remissions in myelofibrosis
December 25, 2013Imetelstat, a novel telomerase-inhibiting drug, has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis, according to a new study. The results were presented at the 2013 ASH Annual Meeting, in New Orleans.
Bortezomib regimen improves stem cell transplantation outcomes
December 25, 2013Adding bortezomib to standard preventive therapy for GVHD results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to research presented at the 2013 ASH Annual Meeting, in New Orleans.
Targeted treatment reduces relapse in children with AML
December 24, 2013Combining the monoclonal antibody gemtuzumab with standard chemotherapy significantly reduced the risk of relapse and increased rates of disease-free survival in pediatric patients with AML. Posttreatment relapse rates are a major indicator of potential for long-term survival in children with the disease.
Umbilical cord blood stem cells treat leukemia and lymphoma
December 20, 2013Growing cord blood stem cells in a laboratory before transplanting them into patients with leukemia, lymphoma, and other blood cancers significantly improves survival, according to a new study.
Less painful drug delivery is safe and effective for pediatric leukemia patients
December 20, 2013Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful IM injection for more than 40 years, research suggests.
Drug-antibody pair has promising activity in non-Hodgkin lymphoma
December 19, 2013A toxin linked to a targeted monoclonal antibody has shown compelling antitumor activity in patients with non-Hodgkin lymphomas (NHLs) who were no longer responding to treatment, according to a new report.
Ibrutinib may be a breakthrough for treatment of a rare lymphoma
January 09, 2013Interim results confirmed the "unprecedented" single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.
Pomalidomide extends survival in multiple myeloma
January 04, 2013A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
Study drug makes marrow transplant possible in relapsed leukemia
January 02, 2013The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
Ibrutinib appears safe, effective against chronic lymphocytic leukemia
December 31, 2012Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
Sign Up for Free e-newsletters
ONA Articles
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Risk of Relapse Up for Young Adults With Leukemia
- Influence of Surgical Options for Early-Stage Lung Cancer on Opioid Use
- Affordable Care Act Has Positive Impact on Outcomes Among Those With Head and Neck Cancer
- Tool Addresses Well-being of Informal Caregivers of Patients With Cancer
- Hematologic Cancers: 8 Tips Oncology Nurses Should Share with Caregivers
- Acrylamide in Food and Cancer Risk (Fact Sheet)
- Tandem Autologous-Allogenic HCT Offers Long-Term Remission in Multiple Myeloma
- Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment
- Advances in Radiogenomics: A Review
- LDR-BT Boost Plus EBRT, ADT Improves Survival in High-Risk Prostate Cancer
- Early Checkpoint Inhibition With Cytotoxic Chemotherapy Improves OS, PFS in Extensive-Stage SCLC
- Aggressive EOL Care Negatively Impacts Care Quality, Health Costs in Metastatic Lung Cancer
- Frequency of Reclassifications of Genetic Testing Results Is Low
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |